A novel chemotype of kinase inhibitors: Discovery of 3,4-ring fused 7-azaindoles and deazapurines as potent JAK2 inhibitors.
Wang, T., Ledeboer, M.W., Duffy, J.P., Pierce, A.C., Zuccola, H.J., Block, E., Shlyakter, D., Hogan, J.K., Bennani, Y.L.(2010) Bioorg Med Chem Lett 20: 153-156
- PubMed: 19945871 
- DOI: https://doi.org/10.1016/j.bmcl.2009.11.021
- Primary Citation of Related Structures:  
3KCK - PubMed Abstract: 
Pictet-Spengler condensation of aldehydes or alpha-keto-esters with 4-(2-anilinophenyl)-7-azaindole (11) or deazapurine (12) gave high yields of the 3,4-fused cyclic compounds. SAR studies, by varying the substituted benzaldehyde components, lead to the discovery of a series of potent JAK2 kinase inhibitors.
Organizational Affiliation: 
Vertex Pharmaceuticals Inc., 130 Waverly St., Cambridge, MA 02139-4242, United States. tiansheng_wang@vrtx.com